Back to top

Analyst Blog

Zacks Equity Research

Quest's New Prenatal Testing Tie Up

DGX ILMN LH

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

A new coalition has been formed between leading diagnostic testing company, Quest Diagnostics (DGX - Analyst Report) and Natera, a genetic testing company with proprietary bioinformatics-based technology ("NATUS"), which offers a complete high-throughput testing for reproductive indications from minute quantities of DNA. As per the newly formed relationship, Natera will get distribution help from Quest Diagnostics, which will offer physicians access to Natera’s latest non-invasive prenatal test Panorama. The terms of the deal were not disclosed.

This test uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with genetic disorders like trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome). Panorama can be used at a very early stage of pregnancy (9th week).

Quest Diagnostics, which is currently striving to expand in women’s health, plans to forward specimens for testing to Natera's CLIA-certified laboratory in Calif. This prenatal test, Panorama, will be available to the clients of Quest Diagnostics in certain regions in Mar and countrywide in Apr 2013.

As per a recent opinion made by the American Congress of Obstetricians and Gynecologists (ACOG), cell-free fetal DNA testing can be used as a primary screening test for women with an increased risk of aneuploidy. It can also act as a follow-up test for women with a positive first-trimester or second-trimester screening test result.

We believe that Quest Diagnostics’ focus on women’s health is necessary as its peers like Illumina’s (ILMN - Analyst Report) plans to acquire Verinata Health, Inc., a privately-held company dedicated to non-invasive tests for the early identification of fetal chromosomal abnormalities. The acquisition was announced a month before. Further, the company’s arch rival – Laboratory Corp. of America Holdings’ (LH - Analyst Report) made an alliance with non-invasive prenatal genetic test company, Ariosa Diagnostics, last year.

Currently, we remain concerned about Quest Diagnostics as it is continuously witnessing challenges with testing volume. Concerns also remain about a conservative 2013 revenue outlook, indicating that the industry trend will not improve in the near future. Although we hold a favorable view regarding the company’s massive organizational restructuring strategy announced in Oct 2012 to increase operational efficiency and restore growth, near-term visibility is discouraging. Moreover, concerns linger regarding the reimbursement cut, which has been in effect from Jan 1, 2013.

The stock currently carries a Zacks Rank #5 (Strong Sell). Another medical device stock, Medical Action Industries Inc. , carries a Zacks Rank #1 (Strong Buy) and appears impressive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%